^
    8d
    Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P1/2, N=34, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • azacitidine
    13d
    P-TRP-2447-14: Hu8F4 in Treating Patients With Advanced Hematologic Malignancies (clinicaltrials.gov)
    P1, N=72, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    Hu8F4
    14d
    Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML (clinicaltrials.gov)
    P=N/A, N=224, Active, not recruiting, Guangdong Provincial People's Hospital
    New trial
    |
    Venclexta (venetoclax) • azacitidine
    15d
    Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) (clinicaltrials.gov)
    P1/2, N=66, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jakafi (ruxolitinib) • Niktimvo (axatilimab-csfr)
    18d
    A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P1, N=50, Recruiting, Dana-Farber Cancer Institute | Active, not recruiting --> Recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    IL2 (Interleukin 2)
    |
    cyclophosphamide • fludarabine IV • CIML NK
    19d
    Understanding Molecular Basis of PTPN11-Related Diseases. (PubMed, ArXiv)
    In this study, we investigate the molecular basis underlying the differential pathogenicity of PTPN11 missense variants and predict the structural consequences of these variants using MutPred2 and AlphaFold2. We find that LOF and GOF variants display distinct functional mechanisms in sodium and DNA binding, and that NS-associated missense variants identified in fetuses with ultrasound-detected anomalies and familiar cases are more likely to be pathogenic.
    Journal
    |
    PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11)
    20d
    VEN-DEC: Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P2, N=235, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 deletion
    |
    Venclexta (venetoclax) • decitabine
    20d
    NCI-2022-03803: A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts (clinicaltrials.gov)
    P2, N=60, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • cladribine • Depocyte (liposomal cytarabine)
    22d
    CBL-Mutated Juvenile Myelomonocytic Leukaemia With Loss of Heterozygosity on 11q Detected by Microarray: Not Always Such a Favourable Outcome. (PubMed, Int J Lab Hematol)
    CN-LOH was confirmed by single nucleotide polymorphism array. This patient presented with an aggressive clinical course and required an allogeneic stem cell transplant.
    Journal
    |
    CBL (Cbl proto-oncogene)
    |
    CBL mutation
    24d
    Concurrent Juvenile Myelomonocytic Leukemia and Gliomas in Patients With Neurofibromatosis Type 1. (PubMed, Pediatr Blood Cancer)
    One notable feature of this cohort is that eight patients (89%) harbored nonsense germline NF1 variants. This case series highlights the emergence of synchronous or metachronous malignancies in children with NF1 and provides a rationale for heightened awareness of this phenomenon.
    Journal
    |
    NF1 (Neurofibromin 1)
    27d
    Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=51, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax)
    27d
    TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, Stanford University
    New P1 trial